CN107118552B - 一种基于明胶和氨基酸的复合膜及在膜上培养角膜缘干细胞的方法 - Google Patents
一种基于明胶和氨基酸的复合膜及在膜上培养角膜缘干细胞的方法 Download PDFInfo
- Publication number
- CN107118552B CN107118552B CN201710301853.2A CN201710301853A CN107118552B CN 107118552 B CN107118552 B CN 107118552B CN 201710301853 A CN201710301853 A CN 201710301853A CN 107118552 B CN107118552 B CN 107118552B
- Authority
- CN
- China
- Prior art keywords
- composite membrane
- amino acid
- gelatin
- reaction
- pegda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 49
- 239000002131 composite material Substances 0.000 title claims abstract description 48
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 38
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 35
- 108010010803 Gelatin Proteins 0.000 title claims abstract description 26
- 239000008273 gelatin Substances 0.000 title claims abstract description 26
- 229920000159 gelatin Polymers 0.000 title claims abstract description 26
- 235000019322 gelatine Nutrition 0.000 title claims abstract description 26
- 235000011852 gelatine desserts Nutrition 0.000 title claims abstract description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 57
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 26
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000047 product Substances 0.000 claims abstract description 20
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000012153 distilled water Substances 0.000 claims abstract description 7
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 5
- 125000004386 diacrylate group Chemical group 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 3
- 230000004048 modification Effects 0.000 claims abstract description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 38
- 239000000178 monomer Substances 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 10
- 210000004087 cornea Anatomy 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 238000006116 polymerization reaction Methods 0.000 claims description 8
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 230000008021 deposition Effects 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 7
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 7
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000006260 foam Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000012265 solid product Substances 0.000 claims description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
- 108010082117 matrigel Proteins 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 239000002798 polar solvent Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 230000001573 trophoblastic effect Effects 0.000 claims description 4
- 102000009016 Cholera Toxin Human genes 0.000 claims description 3
- 108010049048 Cholera Toxin Proteins 0.000 claims description 3
- 229930182555 Penicillin Natural products 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 235000003642 hunger Nutrition 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 101150000157 ARHGEF1 gene Proteins 0.000 abstract description 12
- 238000000506 liquid--solid chromatography Methods 0.000 abstract description 12
- 101150055452 lsc gene Proteins 0.000 abstract description 12
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 abstract description 6
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 239000008363 phosphate buffer Substances 0.000 abstract description 2
- 210000004379 membrane Anatomy 0.000 description 32
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000001291 vacuum drying Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000005081 epithelial layer Anatomy 0.000 description 4
- 210000001232 limbus corneae Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000002734 Collagen Type VI Human genes 0.000 description 3
- 108010043741 Collagen Type VI Proteins 0.000 description 3
- 210000001691 amnion Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000000280 densification Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 206010061213 Iatrogenic injury Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 1
- 101150081664 PAX6 gene Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- -1 methacrylic acid Acid anhydride Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000000016 photochemical curing Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
- C08L77/06—Polyamides derived from polyamines and polycarboxylic acids
- C08L77/08—Polyamides derived from polyamines and polycarboxylic acids from polyamines and polymerised unsaturated fatty acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/28—Treatment by wave energy or particle radiation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/18—Manufacture of films or sheets
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2377/00—Characterised by the use of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Derivatives of such polymers
- C08J2377/06—Polyamides derived from polyamines and polycarboxylic acids
- C08J2377/08—Polyamides derived from polyamines and polycarboxylic acids from polyamines and polymerised unsaturated fatty acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2471/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
- C08J2471/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2489/00—Characterised by the use of proteins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/16—Applications used for films
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/03—Polymer mixtures characterised by other features containing three or more polymers in a blend
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Manufacturing & Machinery (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Materials Engineering (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种基于明胶和氨基酸的复合膜及在膜上培养角膜缘干细胞的方法。所述复合膜是利用明胶、甲基丙烯酸酐,杜氏磷酸缓冲液(DPBS)、蒸馏水在受控条件下制备甲基丙烯酸酐明胶(Gelma);利用聚乙二醇(PEG)、苯、三乙胺、丙烯酰氯、冰乙醚在受控条件下制备聚乙二醇双丙烯酸酯(PEGDA);利用氨基酸,二醇,二酸在受控条件下聚合或者甲基丙烯酸酐修饰获得不饱和聚合物(U‑PEA);最后利用上述反应产物在光引发剂的作用下制备得到复合膜。该复合膜可作为基质层,支撑角膜缘干细胞(LSCs)在膜上生长。本发明操作极为简便,条件简单,重复性好,制备的产品性能可靠,极易实现产业化。
Description
技术领域
本发明属于组织工程技术领域。更具体地,涉及一种基于明胶和氨基酸的复合膜及在膜上培养角膜缘干细胞的方法。
背景技术
角膜是存在于眼球前端的一层透明膜,在空间上具有一定的曲率半径。从生理学的角度上来说,角膜的外层包含了位于中间的连续光滑的上皮层细胞和位于边缘的角膜缘干细胞(LSCs),中间存在一层基质层,占角膜厚度的90%,主要由一型、五型胶原蛋白,粘合物和角化细胞构成。内皮层则由一层六角形内皮细胞所形成,与房水直接相连。角膜缘干细胞能不断向角膜中心分化角膜上皮细胞,对角膜透明、视力的维持起重要作用,而LSCs缺乏是世界性、灾难性的眼科疑难病症,严重威胁人类视觉质量,目前缺乏有效治疗手段。LSCs缺乏的传统的治疗方法包括羊膜移植和LSCs移植。但羊膜移植可导致角膜上皮表型改变,而传统的LSCs移植需要组织多、医源性损伤较大,临床治疗效果均不理想。自体角膜缘组织移植不适合双眼角膜缘病变的患者,异体角膜缘组织移植则存在排斥反应。因此,采用体外培养的角膜缘干细胞移植联合穿透性角膜移植治疗严重的角膜病变,近年来成为人们关注的热点。
对于角膜缘干细胞的培养,目前方法主要采用酶消化法和组织切块法从角膜缘组织上取得原代细胞后滋养在人源羊膜、纤维蛋白胶、等离子聚合物图层,人重组胶原基底物等上。因受限于技术水平,体外培养的角膜缘干细胞都存在厚度过厚,外源性细胞容易引起免疫反应等缺点,使得移植效果并不良好。因此,寻找一种能良好支撑角膜缘干细胞,并使培养的细胞层具有一定的空间曲率,为进一步角膜缘干细胞移植提供条件是一件十分迫切的事情。
组织工程支架材料是指能与组织活体细胞结合并植入生物体的细胞支架。它能支持细胞在其特定的三维构象中增殖和分化。目前组织工程支架材料应用广泛,囊括了骨,软骨,血管,神经,皮肤等各种器官。因此,结合组织工程设计一种支撑材料作为角膜缘干细胞的体外培养基质是一个十分可行的设想。同时,支架材料有以下几点要求:1、支架材料可以控制再生组织的结构,尺寸和外形,引导细胞组织生长分化成特定的形态。2、作为信号分子的载体,携带并缓慢释放生长因子,为细胞分化提供模拟的微环境。3、作为细胞分化代谢的场所,为细胞生长输送营养。4、具有一定的韧性和可加工性,可以适应各组织不同的生理特点。5、具有生物亲和性,并且能随时间在生物体内逐步降解。因此,如何获得具有以上5点技术要求的生物支架材料成为组织工程迫切需要解决的课题。
发明内容
本发明要解决的技术问题是克服上述现有技术的缺陷和不足,创造了一种能支撑角膜缘干细胞体外培养的复合膜,并在此基础上发明了一种在复合膜上培养角膜缘干细胞的方法。所得到的角膜缘干细胞能形成一层致密的上皮层,易于与材料分离,为进一步的临床移植创造了条件。
本发明的目的是提供一种基于明胶和氨基酸的复合膜。
本发明另一目的是提供一种在上述复合膜上培养角膜缘干细胞的方法。
本发明上述目的通过以下技术方案实现:
一种基于明胶和氨基酸的复合膜,是利用明胶、甲基丙烯酸酐,杜氏磷酸缓冲液(DPBS)、蒸馏水在受控条件下制备甲基丙烯酸酐明胶(Gelma);利用聚乙二醇(PEG)、苯、三乙胺、丙烯酰氯、冰乙醚在受控条件下制备聚乙二醇双丙烯酸酯(PEGDA);利用甲基丙烯酸酐对氨基酸在受控条件下进行修饰(U-PEA);最后利用上述反应产物在光引发剂的作用下制备得到。
具体地,所述的复合膜由包括以下步骤的方法制备得到:
S1.合成Gelma材料
利用明胶溶液和甲基丙烯酸酐溶液反应,反应产物透析干燥后得到白色多孔泡沫产物即为Gelma材料;于低温干燥处储存;
S2.合成PEGDA
PEG与苯混合,于避光下加入三乙胺和丙烯酰氯冰浴反应,反应后抽滤除去不溶性盐,并用冰乙醚对滤液进行后处理,所得固体产物即为PEGDA,真空干燥后于干燥处避光保存;
S3.合成含有不饱和键的氨基酸聚合物
氨基酸、二醇和对甲苯磺酸反应制备成单体A,不饱和二酸酰氯与对硝基苯酚制备成单体B,单体A和单体B聚合反应,产物沉淀纯化即得含有不饱和键的氨基酸聚合物;
S4.利用上述步骤S1、S2、S3的产物制备复合膜
用40~50℃的纯水溶解消毒PEGDA、Gelma材料和含有不饱和键的氨基酸聚合物后混合,加入光引发剂,紫外光照即得到Gelma/PEGDA复合膜。
更具体优选地,步骤S1所述合成Gelma材料的具体方法为:将质量体积浓度为5~15%的明胶PBS溶液在5~15℃水浴中溶解后,以0.1~1mL/min的速度加入体积比为5~30%的甲基丙烯酸酐,在50℃水浴中搅拌反应4~24h,加5倍量DPBS停止反应;将所得液体置于8~14KD透析袋中,于蒸馏水中透析3,经冷冻干燥后得到白色多孔泡沫产物即为Gelma材料,于低温干燥处下储存。
优选地,步骤S1所述明胶的分子量为1万~30万,胶强度为50~400g Bloom。
优选地,步骤S2所述合成PEGDA的具体方法为:PEG加入苯溶剂中,在油浴蒸馏使除去水后冷却至室温,于避光加入三乙胺和丙烯酰氯冰浴反应4~48h,反应后抽滤除去不溶性盐,并用冰乙醚对滤液进行后处理,所得固体产物即为PEGDA,真空干燥后于干燥处避光保存;其中,PEG在苯溶剂里面的质量体积比浓度为3~20%,PEG:三乙胺:丙烯酰氯的摩尔比为1:4~10:4~10。
优选地,步骤S2中,PEG分子量为1000~50000。
优选地,步骤S3所述合成含有不饱和键的氨基酸聚合物的具体方法为:氨基酸、二醇和对甲苯磺酸在有机溶剂一中反应制备成单体A,不饱和二酸酰氯与对硝基苯酚制备成单体B,单体A和单体B溶于有机溶剂二中聚合反应,反应温度为50~150℃,反应后于烘箱里保存过夜,产物用乙酸乙酯沉淀纯化即得含有不饱和键的氨基酸聚合物;其中所述有机溶剂一为苯或者甲苯,所述有机溶剂二为含有三乙胺或其他中和试剂的DMF、DMSO及DMA等强极性溶剂。
优选地,所述氨基酸为精氨酸、苯丙氨酸或者甘氨酸。
优选地,步骤S4所述制备复合膜的具体方法为:用40~50℃的纯水溶解消毒过的PEGDA、Gelma材料和含有不饱和键的氨基酸聚合物混合,加入光引发剂,将混合液注入模具紫外光照10~300s即可制成膜。
其中,优选地,PEGDA:Gelma材料:含有不饱和键的氨基酸聚合物的质量比为0.1~75%:0.1~75%:0.1~90%。
优选地,光引发剂的使用量为复合膜质量的0.05~5%。
另外,一种角膜缘干细胞的培养基,配方比例为:100IU青霉素,100μg/ml链霉素,10~20ng/ml人重组EGF,5~10μg/ml胰岛素,1~5×10-9M 3-碘甲状腺原氨酸,0.2~1μg/ml氢化可的松,1~5×10-9M霍乱毒素,余量为DMEM和/或DMEM/F12。
更优选地,所述角膜缘干细胞的培养基的配方比例为:每500mL培养基含有5mL 10×双抗(青霉素和链霉素)、1mL人重组EGF、1mL胰岛素、1mL 3-碘甲状腺原氨酸、1mL氢化可的松、1mL霍乱毒素,220mL DMEM、220mL DMEM/F12、50mL FBS。
另外,在上述制备了所述复合膜的基础上,本发明还提供了一种不需要滋养层的角膜缘干细胞体外培养方法,是将角膜缘组织用PBS清理后,用手术刀切碎后用IV型胶原蛋白酶进行酶解,酶解后的产物置于权利要求7所述的培养基中进行培养。
其中,优选地,所述IV型胶原蛋白酶的浓度为0.1~0.3%。
优选地,酶解时间为1~3h。
更优选地,所述IV型胶原蛋白酶的浓度为0.2%,酶解时间为2h。
优选地,将酶解后的产物置于培养基中进行培养之前,先加入Matrigel和复合膜,35~38℃孵育5~15分钟(优选37℃孵育10分钟),再加入分离后的角膜缘干细胞。
即更优选地,所述不需要滋养层的角膜缘干细胞体外培养方法包括如下步骤:
(1)将角膜缘组织用PBS清理后,用手术刀切碎后进行酶解;使用的酶为IV型胶原蛋白酶,置于37℃震荡摇床,酶解时间为2小时;加入含10%FBS的DMEM终止酶解,1000rpm离心5min,弃上清;
(3)用上述角膜缘干细胞的培养基,将酶解离心得到的角膜缘干细胞重悬;
(4)将Gelma/PEGDA复合膜与10%的Matrigel溶液平铺于6孔板中,于37℃温箱静置10分钟后吸干剩余的Matrigel溶液;
(5)将重悬的角膜缘干细胞种植于铺了复合膜的6孔板中,置于37℃,5%CO2培养箱中培养,隔天换液,并在显微镜中观察细胞的生长状态。
本发明在寻找一种能提供给角膜缘干细胞体外培养使用的复合膜的制备方法的过程中发现,角膜中角膜外皮细胞和角膜缘干细胞都依托生长于基质层上,而基质层的主要成分为胶原蛋白;鉴于明胶的成分也主要来自于天然的胶原蛋白,因而将其作为支撑角膜缘干细胞体外培养的基底是可行的。但是由于明胶的机械稳定性较差,本发明引入了能在紫外光下固化交联的PEGDA来增强明胶的机械稳定性。该方法可制得具有较好物理学形状和生物学功能的承载材料。
本发明具有以下有益效果:
本发明首先利用聚乙二醇双丙烯酸酯(PEGDA)、甲基丙烯酸酯明胶(Gelma)和含有不饱和键的氨基酸聚合物在受控的条件下合成了一种复合膜,除了具备传统水凝胶便于固型、高生物相容性的优点外,其新优点在于:
(1)光固化的特性使其在应用过程中更加便于对成品参数的精调整。在紫外光照射前,可以方便的将材料注入到特定形状,特定厚度的透明模具中固化。
(2)制备过程中修饰过的氨基酸聚合物的加入,使复合膜能提供促进细胞分化的微环境。
(3)明胶作为天然材料虽然与人体组织具有相同或者相近的化成成分,但是由于是非共价键交联,存在着极不稳定的特定,聚乙二醇双丙烯酸酯具有生物相容性且通过化学键交联,在机械性质上更加稳定。因此,本方法综合了这两种材料的优点。
另外,在制备了上述复合膜的基础上,本发明还提供了一种不需要滋养层的角膜缘干细胞体外培养方法,该LSCs体外培养的方法无滋养层,细胞生长在前文所述的复合膜上,便于运输。在37摄氏度,5%CO2的条件下能形成一层致密的上皮层,易于从复合材料上分离,为进一步移植创造有利条件。
附图说明
图1:a,b为固化之后从模具中取出的复合膜。
图2:a,b为封装好的复合膜。
图3:取膜的过程。
图4:在7.5%Gelma+2.5%PEG的膜上体外培养的角膜缘干细胞和角膜上皮细胞。
图5:a为膜上体外培养的角膜缘干细胞LSC标记物Pax6的染色图;b为角膜特异性角蛋白基因K3/K12的染色图;证明LSC能成功适应复合膜的环境,正常增殖。
图6:一层取自复合膜体上外培养的LSCs,形成了一片致密的上皮层。
具体实施方式
以下结合说明书附图和具体实施例来进一步说明本发明,但实施例并不对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
除非特别说明,以下实施例所用试剂和材料均为市购。
本发明制备得到的复合膜以及利用该复合膜培养角膜缘干细胞的结果如附图1~6所示,具体实施案例如下所述:
实施例1制备复合膜
将10%(W/V)的明胶PBS溶液在10℃水浴中溶解后,以0.5mL/min的速度加入体积比为5%的甲基丙烯酸酐,在50℃水浴中搅拌反应24h后加5倍量的DPBS停止反应。将所得液体置于8~14KD透析袋中,于蒸馏水中透析3d后经冷冻干燥后得到白色多孔泡沫产物即为Gelma材料,于低温干燥处下储存。
PEG与苯按照20%(W/V)比例混合,在油浴蒸馏使除去水后冷却至室温,于避光加入三乙胺和丙烯酰氯冰浴反应48h(PEG:三乙胺:丙烯酰氯的摩尔比为1:4:4),反应后抽滤除去不溶性盐,并用冰乙醚对滤液进行后处理,所得固体产物即为PEGDA,真空干燥后于干燥处避光保存。
精氨酸、二醇和对甲苯磺酸在有机溶剂(苯或者甲苯)中反应制备成单体A,不饱和二酸酰氯与对硝基苯酚制备成单体B,单体A和单体B溶于有机溶剂(含有三乙胺或其他中和试剂的DMF、DMSO及DMA等强极性溶剂)中聚合反应,反应温度为50~150℃,反应后于烘箱里保存过夜,产物用乙酸乙酯沉淀纯化即得含有不饱和键的氨基酸聚合物。
用50℃的纯水溶解消毒过的PEGDA、Gelma和含有不饱和键的氨基酸聚合物(各组成成分含量为25%:10%:65%),加入0.5%(W/W)的光引发剂,将混合液注入模具紫外光照(100s)即可制成膜,即为Gelma/PEGDA。
实施例2制备复合膜
将10%(W/V)的明胶PBS溶液在10℃水浴中溶解后,以0.5mL/min的速度加入体积比为5%的甲基丙烯酸酐,在50℃水浴中搅拌反应24h后加5倍量的DPBS停止反应。将所得液体置于8~14KD透析袋中,于蒸馏水中透析3d后经冷冻干燥后得到白色多孔泡沫产物即为Gelma材料,于低温干燥处下储存。
PEG与苯按20%(W/V)比例混合,在油浴蒸馏使除去水后冷却至室温,于避光加入三乙胺和丙烯酰氯冰浴反应48h(PEG:三乙胺:丙烯酰氯的摩尔比为1:4:4),反应后抽滤除去不溶性盐,并用冰乙醚对滤液进行后处理,所得固体产物即为PEGDA,真空干燥后于干燥处避光保存。
苯丙氨酸、二醇和对甲苯磺酸在有机溶剂(苯或者甲苯)中反应制备成单体A,不饱和二酸酰氯与对硝基苯酚制备成单体B,单体A和单体B溶于有机溶剂(含有三乙胺或其他中和试剂的DMF、DMSO及DMA等强极性溶剂)中聚合反应,反应温度为50~150℃,反应后于烘箱里保存过夜,产物用乙酸乙酯沉淀纯化即得含有不饱和键的氨基酸聚合物
用50℃的纯水溶解消毒过的PEGDA、Gelma和含有不饱和键的氨基酸聚合物(各组成成分含量为25%:10%:65%),加入0.5%(W/W)的光引发剂,将混合液注入模具紫外光照(100s)即可制成膜,即为Gelma/PEGDA。
实施例3制备复合膜
将10%(W/V)的明胶PBS溶液在10℃水浴中溶解后,以0.5mL/min的速度加入体积比为5%的甲基丙烯酸酐,在50℃水浴中搅拌反应24h后加5倍量的DPBS停止反应。将所得液体置于8~14KD透析袋中,于蒸馏水中透析3d后经冷冻干燥后得到白色多孔泡沫产物即为Gelma材料,于低温干燥处下储存。
PEG与苯按20%(W/V)比例混合,在油浴蒸馏使除去水后冷却至室温,于避光加入三乙胺和丙烯酰氯冰浴反应48h(PEG:三乙胺:丙烯酰氯的摩尔比为1:4:4),反应后抽滤除去不溶性盐,并用冰乙醚对滤液进行后处理,所得固体产物即为PEGDA,真空干燥后于干燥处避光保存。
甘氨酸、二醇和对甲苯磺酸在有机溶剂(苯或者甲苯)中反应制备成单体A,不饱和二酸酰氯与对硝基苯酚制备成单体B,单体A和单体B溶于有机溶剂(含有三乙胺或其他中和试剂的DMF、DMSO及DMA等强极性溶剂)中聚合反应,反应温度为50~150℃,反应后于烘箱里保存过夜,产物用乙酸乙酯沉淀纯化即得含有不饱和键的氨基酸聚合物
用50℃的纯水溶解消毒过的PEGDA、Gelma和含有不饱和键的氨基酸聚合物(各组成成分含量为25%:10%:65%),加入0.5%(W/W)的光引发剂,将混合液注入模具紫外光照(100s)即可制成膜,即为Gelma/PEGDA。
实施例4角膜缘干细胞体外培养方法
1、一种角膜缘干细胞的培养基,培养基中含有以下组分:每500mL培养基含有5mL10×双抗、1mL人重组EGF、1mL胰岛素、1mL 3-碘甲状腺原氨酸、1mL氢化可的松、1mL霍乱毒素,220mL DMEM、220mL DMEM/F12、50mL FBS。
2、角膜缘干细胞体外培养方法
(1)将角膜缘组织用PBS清理后,用手术刀切碎后进行酶解;使用的酶为IV型胶原蛋白酶,置于37℃震荡摇床,酶解时间为2小时;加入含10%FBS的DMEM终止酶解,1000rpm离心5min,弃上清;
(3)用上述角膜缘干细胞的培养基,将酶解离心得到的角膜缘干细胞重悬;
(4)将Gelma/PEGDA复合膜与10%的Matrigel溶液平铺于6孔板中,于37℃温箱静置10分钟后吸干剩余的Matrigel溶液;
(5)将重悬的角膜缘干细胞种植于铺了复合膜的6孔板中,置于37℃,5%CO2培养箱中培养,隔天换液,并在显微镜中观察细胞的生长状态。
3、结果如附图4~6所示。结果显示,LSC能成功适应复合膜的环境,正常增殖;而且复合膜体上外培养的LSCs形成了一片致密的上皮层。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (8)
1.一种基于明胶和氨基酸的复合膜,其特征在于,是利用明胶、甲基丙烯酸酐,杜氏磷酸缓冲液、蒸馏水在受控条件下制备甲基丙烯酸酐明胶;利用聚乙二醇、苯、三乙胺、丙烯酰氯、冰乙醚在受控条件下制备聚乙二醇双丙烯酸酯;利用氨基酸,二醇,二酸在受控条件下聚合或者甲基丙烯酸酐修饰获得不饱和聚合物;最后利用上述反应产物在光引发剂的作用下制备得到。
2.根据权利要求1所述的复合膜,其特征在于,由包括以下步骤的方法制备得到:
S1.合成Gelma材料:利用明胶溶液和甲基丙烯酸酐溶液反应,反应产物透析干燥后得到白色多孔泡沫产物即为Gelma材料;
S2.合成PEGDA:PEG与苯混合,于避光下加入三乙胺和丙烯酰氯冰浴反应,反应后抽滤除去不溶性盐,并用冰乙醚对滤液进行后处理,所得固体产物即为PEGDA;
S3.合成含有不饱和键的氨基酸聚合物:氨基酸、二醇和对甲苯磺酸反应制备成单体A,不饱和二酸酰氯与对硝基苯酚制备成单体B,单体A和单体B聚合反应,产物沉淀纯化即得含有不饱和键的氨基酸聚合物;
S4.制备复合膜:用40~50℃的纯水溶解消毒PEGDA、Gelma材料和含有不饱和键的氨基酸聚合物后混合,加入光引发剂,紫外光照即得到Gelma/PEGDA复合膜。
3.根据权利要求2所述的复合膜,其特征在于,步骤S1所述合成Gelma材料的具体方法为:将质量体积浓度为5~15%的明胶PBS溶液在5~15℃水浴中溶解后,以0.1~1mL/min的速度加入体积比5~30%的甲基丙烯酸酐,在50℃水浴中搅拌反应4~24h,所得液体透析后,经冷冻干燥得到白色多孔泡沫产物即为Gelma材料。
4.根据权利要求2所述的复合膜,其特征在于,步骤S2所述合成PEGDA的具体方法为:PEG加入苯溶剂中,在油浴蒸馏使除去水后冷却至室温,于避光下加入三乙胺和丙烯酰氯,冰浴反应4~48h,反应后抽滤除去不溶性盐,并用冰乙醚对滤液进行后处理,所得固体产物即为PEGDA;其中,PEG在苯溶剂里面的质量体积比浓度为3~20%,PEG:三乙胺:丙烯酰氯的摩尔比为1:4~10:4~10。
5.根据权利要求2所述的复合膜,其特征在于,步骤S3所述合成含有不饱和键的氨基酸聚合物的具体方法为:氨基酸、二醇和对甲苯磺酸在有机溶剂一中反应制备成单体A,不饱和二酸酰氯与对硝基苯酚制备成单体B,单体A和单体B溶于有机溶剂二中聚合反应,反应温度为50~150℃,产物用乙酸乙酯沉淀纯化即得含有不饱和键的氨基酸聚合物;其中所述有机溶剂一为苯或者甲苯,所述有机溶剂二为含有三乙胺或其他中和试剂的DMF、DMSO或DMA强极性溶剂。
6.根据权利要求2所述的复合膜,其特征在于,步骤S4所述制备复合膜的具体方法为:将用40~50℃的纯水溶解消毒过的PEGDA、Gelma材料和含有不饱和键的氨基酸聚合物混合,加入光引发剂,紫外光照10~300s即制得复合膜。
7.权利要求1~6任一所述复合膜在体外培养角膜缘干细胞方面的应用。
8.一种不需要滋养层的角膜缘干细胞体外培养方法,其特征在于,是将角膜缘组织用PBS清理后,切碎后用IV型胶原蛋白酶进行酶解,酶解后的产物置于培养基中,先加入Matrigel和权利要求1~6任一所述复合膜,35~38℃孵育5~15分钟,再加入分离后的角膜缘干细胞,然后进行培养;所述IV型胶原蛋白酶的浓度为0.1~0.3%,酶解时间为1~3h;
其中,所述培养基包含如下组分:100 IU 青霉素,100µg/ml链霉素,10~20ng/ml人重组EGF,5~10µg/ml胰岛素,1~5×10-9M 3-碘甲状腺原氨酸,0.2~1µg/ml 氢化可的松,1~5×10-9M霍乱毒素,余量为DMEM和/或 DMEM/F12。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710301853.2A CN107118552B (zh) | 2017-05-02 | 2017-05-02 | 一种基于明胶和氨基酸的复合膜及在膜上培养角膜缘干细胞的方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710301853.2A CN107118552B (zh) | 2017-05-02 | 2017-05-02 | 一种基于明胶和氨基酸的复合膜及在膜上培养角膜缘干细胞的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107118552A CN107118552A (zh) | 2017-09-01 |
| CN107118552B true CN107118552B (zh) | 2018-12-18 |
Family
ID=59726610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710301853.2A Active CN107118552B (zh) | 2017-05-02 | 2017-05-02 | 一种基于明胶和氨基酸的复合膜及在膜上培养角膜缘干细胞的方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107118552B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108084466B (zh) * | 2017-12-06 | 2021-06-29 | 中山大学 | 一种基于蛋清和甲基丙烯酸衍生化聚合物的复合膜及其在培养干细胞方面的应用 |
| CN108653809B (zh) * | 2018-05-23 | 2021-07-16 | 中山大学 | 一种基于黑磷和明胶的复合水凝胶及其在骨组织工程方面的应用 |
| CN109554340A (zh) * | 2018-11-27 | 2019-04-02 | 华中科技大学 | 一种基于静电纺丝混合纤维膜构建组织工程角膜缘的方法 |
| CN114681146A (zh) * | 2020-12-31 | 2022-07-01 | 杭州启明医疗器械股份有限公司 | 生物组织的预处理方法、交联改性方法、生物组织预制品及生物组织 |
| CN114796604B (zh) * | 2021-06-08 | 2023-04-07 | 天津大学 | 一种用于角膜再生的3d打印墨水及其制备方法和应用 |
| CN114479126B (zh) * | 2022-03-07 | 2024-04-12 | 成都福实生物科技有限公司 | 一种制备可模拟体内ecm刚度微环境的水凝胶的方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63215641A (ja) * | 1987-03-05 | 1988-09-08 | Toyo Jozo Co Ltd | ゼラチン皮膜組成物 |
| CN1635115A (zh) * | 2004-05-27 | 2005-07-06 | 天津医科大学眼科中心 | 人成纤维细胞滋养的人角膜缘干细胞组织工程产品及制备 |
| CN101121926A (zh) * | 2007-07-02 | 2008-02-13 | 西北农林科技大学 | 一种角膜缘干细胞无血清培养基 |
| CN101543643B (zh) * | 2009-04-02 | 2012-10-10 | 天津大学 | 具有生物活性的胶原基复合角膜替代物及其制备方法 |
| JP6048811B2 (ja) * | 2012-11-22 | 2016-12-21 | 国立研究開発法人物質・材料研究機構 | 組織接着膜及びその製造方法 |
| CN103898056B (zh) * | 2014-03-11 | 2016-09-07 | 山东大学附属千佛山医院 | 细胞培养基及其在培养人原代肿瘤细胞中的应用 |
| CN105219704A (zh) * | 2015-11-16 | 2016-01-06 | 广州赛莱拉干细胞科技股份有限公司 | 角膜缘干细胞的分离方法 |
-
2017
- 2017-05-02 CN CN201710301853.2A patent/CN107118552B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107118552A (zh) | 2017-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107118552B (zh) | 一种基于明胶和氨基酸的复合膜及在膜上培养角膜缘干细胞的方法 | |
| Yu et al. | Effects of 3-dimensional bioprinting alginate/gelatin hydrogel scaffold extract on proliferation and differentiation of human dental pulp stem cells | |
| Jin et al. | Three-dimensional bioprinting of a full-thickness functional skin model using acellular dermal matrix and gelatin methacrylamide bioink | |
| CA2848405C (en) | Fabrication of gelatin hydrogel sheet for the transplantation of corneal endothelium | |
| Liang et al. | Fabrication and characters of a corneal endothelial cells scaffold based on chitosan | |
| KR101613478B1 (ko) | 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 | |
| CN101757691B (zh) | 一种组织工程角膜的制备方法 | |
| JP6010460B2 (ja) | フィブリンおよびアガロース生体材料を用いる組織工学による、人工組織の製造 | |
| Khalili et al. | Corneal endothelium tissue engineering: An evolution of signaling molecules, cells, and scaffolds toward 3D bioprinting and cell sheets | |
| CN105079783B (zh) | 药物组合物及其制备方法和用途 | |
| JPS6339583A (ja) | 細胞・組織の基体への付着方法 | |
| CN101629162B (zh) | 组织工程细胞片及其制备方法 | |
| KR101585032B1 (ko) | 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 | |
| ES2681443T3 (es) | Andamiaje de glucomanano para el cultivo e ingeniería de tejidos tridimensionales | |
| Ermis | Photo-crosslinked gelatin methacrylate hydrogels with mesenchymal stem cell and endothelial cell spheroids as soft tissue substitutes | |
| Lai | Influence of solvent composition on the performance of carbodiimide cross-linked gelatin carriers for retinal sheet delivery | |
| Wei et al. | Hydrogels to support transplantation of human embryonic stem cell-derived retinal pigment epithelial cells | |
| WO2018069563A1 (es) | Membranas bioartificiales de rigidez y viscoelasticidad controlada para su utilización en ingeniería tisular | |
| Lin et al. | Evaluation of adhesion, proliferation, and differentiation of human adipose-derived stem cells on keratin | |
| CN104971382A (zh) | 一种用无血清和牛垂体提取物培养液构建的创口贴式人工活性组织及其构建方法 | |
| CN105963795A (zh) | 一种基于胶原制备组织工程表皮的方法 | |
| JP6616559B2 (ja) | シート状細胞培養物の製造方法 | |
| US20240307591A1 (en) | Accelerated Development of Functional Three-Dimensional Tissue Moduli | |
| CN110229783A (zh) | 一种基于温皿制备干细胞膜片的方法 | |
| Grolik et al. | Silicone-modified chitosan membranes for corneal epithelium tissue engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |